You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR FLUDROCORTISONE ACETATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Fludrocortisone Acetate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00118482 ↗ Clinical Trial for the Prevention of Vasovagal Syncope Completed Canadian Institutes of Health Research (CIHR) Phase 4 2005-05-01 The main question in the study is whether people taking fludrocortisone are less likely to faint than people taking an inactive pill called a placebo. Fludrocortisone is a drug that stimulates the body to retain salt and water. The investigators know from some studies that it might prevent people from fainting at home and in the community, while they are carrying on with their lives. There is some evidence that salt and water retention help prevent fainting, but no one has a clear idea about whether this is true. This study will try to determine if that is true.
NCT00118482 ↗ Clinical Trial for the Prevention of Vasovagal Syncope Completed University of Calgary Phase 4 2005-05-01 The main question in the study is whether people taking fludrocortisone are less likely to faint than people taking an inactive pill called a placebo. Fludrocortisone is a drug that stimulates the body to retain salt and water. The investigators know from some studies that it might prevent people from fainting at home and in the community, while they are carrying on with their lives. There is some evidence that salt and water retention help prevent fainting, but no one has a clear idea about whether this is true. This study will try to determine if that is true.
NCT01495910 ↗ A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency Completed Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Phase 1 2011-12-01 The purpose of this study is to determine the minimum dose of abiraterone acetate needed to decrease serum androstenedione to age-appropriate levels in premenopausal women on steroid replacement for classic 21-hydroxylase deficiency.
NCT02017197 ↗ Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Fundação de Amparo à Pesquisa do Estado de São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗ Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Federal University of São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02574910 ↗ Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 Active, not recruiting Children's Hospital Los Angeles Phase 1 2017-08-01 Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height. Additionally, these children require supraphysiologic doses of hydrocortisone to suppress secretion of adrenal androgen precursors, and this treatment can retard linear growth. This study seeks to use oral abiraterone acetate (Zytiga)as an adjunct to approved CAH therapy (oral hydrocortisone and fludrocortisone) for pre-pubescent children with classic 21-hydroxylase deficiency in order to reduce daily requirement of hydrocortisone. In this Phase 1 study, the investigators will determine the minimum effective dose of abiraterone acetate that normalizes androstenedione levels during the 7-day Treatment Period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fludrocortisone Acetate

Condition Name

Condition Name for Fludrocortisone Acetate
Intervention Trials
Prostatic Neoplasms 3
Congenital Adrenal Hyperplasia 2
Metastatic Castration-Resistant Prostate Cancer 2
Septic Shock 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fludrocortisone Acetate
Intervention Trials
Prostatic Neoplasms 4
Adrenal Hyperplasia, Congenital 3
Adrenogenital Syndrome 3
Hyperplasia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fludrocortisone Acetate

Trials by Country

Trials by Country for Fludrocortisone Acetate
Location Trials
United States 39
China 18
United Kingdom 12
Japan 10
Australia 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fludrocortisone Acetate
Location Trials
Maryland 4
Texas 4
Michigan 4
California 3
Virginia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fludrocortisone Acetate

Clinical Trial Phase

Clinical Trial Phase for Fludrocortisone Acetate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fludrocortisone Acetate
Clinical Trial Phase Trials
Recruiting 4
Completed 3
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fludrocortisone Acetate

Sponsor Name

Sponsor Name for Fludrocortisone Acetate
Sponsor Trials
Orion Corporation, Orion Pharma 4
Merck Sharp & Dohme LLC 4
Feinstein Institute for Medical Research 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fludrocortisone Acetate
Sponsor Trials
Other 13
Industry 9
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.